The new study confirms the benefits of cabazitaxel in the third-line setting in a real-world population. The report was published as a preprint and has not yet been peer-reviewed.
First Look
The new study confirms the benefits of cabazitaxel in the third-line setting in a real-world population. The report was published as a preprint and has not yet been peer-reviewed.
First Look
